Abstract: Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines.

Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.

Abstract: Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.

Abstract: The present invention relates to the field of arbovirosis caused by Chikungunya virus (CHIK). The present invention specifically concerns anti-CHIK monoclonal antibodies (MAbs), and more specifically anti-CHIK.E2 MAbs and their use as diagnostic products in methods for detecting the presence or absence of a CHIK strain.

Abstract: The present invention relates to a vaccine composition against feline calicivirus (CFV) infection. The composition comprises a capsid protein of Feline calicivirus-49 (CFV-49), a pharmaceutical accepted carrier and optionally an adjuvant. The present invention further relates to a feline vaccine composition further comprises other live, attenuated or inactivated CVF component in addition to the capsid protein of FCV-49. The present invention also relates to a method for making or using the vaccine compositions.

Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.

Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.

Abstract: The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Abstract: E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV strain Brescia during infection in the natural host. The three putative glycosylation sites in E1 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E1 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all three putative glycosylation sites in E1. Single mutations of each of the E1 glycosylation sites showed that CSFV amino acid N594 (E1.N3 virus), as well the combined mutation of N500 and N513 (E1.N1N2 virus) resulted in BICv attenuation.

Abstract: Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.

Abstract: The invention relates to a method of treating cancer, comprising administering to a subject in need thereof an effective amount of a HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10. The invention further relates to pharmaceutical compositions comprising HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10.

Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Abstract: Since FIV-vaccinated cats produce antibodies against FIV, distinguishing them from FIV-infected cats is difficult by serological diagnostic methods using FIV and FIV-derived substances. The present invention enables tests for determining the presence or absence of a FIV vaccination history in a cat by detecting antibodies that are produced as a result of vaccination of a cat with an FIV vaccine, but not as a result of FIV infection. Using the methods of the present invention, whether an anti-FIV antibody-positive cat is infected with FIV or has been vaccinated can be conveniently distinguished.

Abstract: Whole organisms are inactivated by at least a factor of 106 using carbon dioxide at or near its supercritical pressure and temperature conditions.

Abstract: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficie

Abstract: A non-human animal disease model for hepatitis B virus-associated liver disease is disclosed. The animal disease model is transduced with a hepatitis B virus genome in the liver cells thereof and exhibits the following symptoms: hepatitis B viral particles and hepatitis B viral DNA in the serum, hepatitis B virus (HBV) envelope and HBV e proteins in the serum, expression of HBV core and HBV envelope proteins in the liver but not in the kidney, heart, lung, brain, pancreas, spleen, stomach or intestine tissues. The animal disease model may develop hepatocellular carcinoma, exhibiting an elevated level of alanine aminotransferase as compared to a control animal without the hepatitis B virus genome in the liver cells thereof, and liver pathological symptoms such as tumor nodules, dysplasia, inflammatory infiltrates, necrosis and fibrosis.

Abstract: The present invention relates to a system for the heterologous expression of a viral protein or a fragment thereof, said system comprising a) a ciliate host cell, b) at least one cDNA encoding for a viral protein, or a fragment thereof, and c) a promoter operably linked to said cDNA.

Abstract: A new clone of Newcastle disease virus which is interferon insensitive and has an ICPI between 1.2 and 2.0 and which may be used in the treatment of cancer and other diseases.

Abstract: The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B-and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.